Provided by Tiger Trade Technology Pte. Ltd.

VistaGen Therapeutics

0.2438
-0.0002-0.08%
Pre-market: 0.24780.0040+1.64%04:00 EDT
Volume:477.88K
Turnover:115.44K
Market Cap:10.82M
PE:-0.15
High:0.2481
Open:0.2394
Low:0.2355
Close:0.2440
52wk High:5.14
52wk Low:0.1980
Shares:44.38M
Float Shares:41.42M
Volume Ratio:0.44
T/O Rate:1.15%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6559
EPS(LYR):-1.8303
ROE:-166.46%
ROA:-83.21%
PB:0.44
PE(LYR):-0.13

Loading ...

Inflammation Drug Developer HCW Biologics' Q2 Net Loss Widens

Reuters
·
Aug 15

VistaGen Therapeutics Q1 EPS $(0.30) Beats $(0.36) Estimate, Sales $1.476M Beat $250.000K Estimate

Benzinga Earnings
·
Aug 14

VistaGen Q1 Revenue Rises on Licensing Agreement Expiration

Reuters
·
Aug 14

VistaGen Q1 EPS USD -0.3

Reuters
·
Aug 14

Vistagen Q1 Net Income USD -13.03 Million

THOMSON REUTERS
·
Aug 14

Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update

THOMSON REUTERS
·
Aug 14

Analysts’ Opinions Are Mixed on These Healthcare Stocks: VistaGen Therapeutics (VTGN), Iovance Biotherapeutics (IOVA) and Aurinia Pharmaceuticals (AUPH)

TIPRANKS
·
Aug 06

Vistagen announces topline results from fasedienol repeat dose study

TIPRANKS
·
Aug 06

VistaGen Says Phase 2 Repeat-Dose Fasedienol Study in Social Anxiety Disorder Shows Favorable Safety, Efficacy Signals

Reuters
·
Aug 06

Vistagen Therapeutics - Repeat Dose Fasedienol Demonstrates Favorable Safety and Tolerability Similar to Single Dose

THOMSON REUTERS
·
Aug 06

Vistagen Therapeutics - Nominally Statistically Significant Improvement in Very Severe Social Anxiety Disorder Patients

THOMSON REUTERS
·
Aug 06

Vistagen Therapeutics - Efficacy Signals Observed Across Primary and Secondary Endpoints for Fasedienol

THOMSON REUTERS
·
Aug 06

Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder

THOMSON REUTERS
·
Aug 06

VistaGen Gets NASDAQ Extension to Regain $1 Minimum Bid Price Compliance

Reuters
·
Aug 06

Top Premarket Gainers

MT Newswires Live
·
Aug 04

SRX Global acquires stake in Vistagen

TIPRANKS
·
Aug 04

SRX Global Acquires Stake in Vistagen Therapeutics

Reuters
·
Aug 04

Srx Global Acquires Stake in Vistagen Therapeutics (Nasdaq: Vtgn)

THOMSON REUTERS
·
Aug 04

Vistagen Therapeutics Inc Expected to Post a Loss of 36 Cents a Share - Earnings Preview

Reuters
·
Aug 04

VistaGen Announces Annual Shareholder Meeting

Reuters
·
Aug 01